MET and cancer: We have previously shown that SEMA3C is an autocrine growth factor that drives cancer growth and treatment resistance through the transactivation of multiple receptor tyrosine kinases (RTK) such as HER2, Epidermal Growth Factor Receptor (EGFR), and hepatocyte growth factor receptor (MET) in a cognate ligand independent manner [10,12].